Rhesus hemolytic disease, also known as hemolytic disease of the fetus and newborn (HDFN), is a condition caused by maternal antibodies attacking fetal red blood cells when the mother is Rh-negative and the fetus is Rh-positive. This occurs due to Rh antigen exposure during pregnancy or delivery, leading to immune-mediated destruction of fetal erythrocytes.
The condition arises when Rh-negative mothers develop IgG antibodies against the Rh(D) antigen present on Rh-positive fetal red blood cells. These antibodies cross the placenta and bind to fetal erythrocytes, marking them for destruction by the fetal spleen and liver. The resulting anemia can progress to hydrops fetalis-fluid accumulation in fetal tissues-and, if untreated, stillbirth or severe neonatal complications.
Without intervention, rhesus hemolytic disease affects approximately 1 in 1,000 pregnancies globally. However, routine antenatal administration of anti-D immunoglobulin has reduced incidence to less than 1 in 10,000 in countries with universal screening programs. The condition remains a leading cause of fetal morbidity in regions with limited access to prenatal care.
During pregnancy, small amounts of fetal blood may enter the maternal circulation, especially during amniocentesis, vaginal bleeding, or delivery. In Rh-negative individuals, this exposure triggers B-cell activation and IgG antibody production against the Rh(D) antigen. The primary immune response takes weeks to develop, but subsequent pregnancies elicit a faster, stronger secondary response.
Once maternal IgG antibodies cross the placenta-typically after 16 weeks gestation-they bind to Rh(D)-positive red blood cells in the fetus. Complement activation and opsonization lead to phagocytosis by macrophages in the reticuloendothelial system. Hemolysis results in elevated bilirubin levels, which can cause kernicterus if unchecked.
A 2020 study published in The Lancet found that 85% of cases detected prenatally involved antibody titers above 1:16, indicating high-risk status. Early detection via serial antibody testing enables timely management, including intrauterine transfusions when necessary.
There is no formal classification into subtypes, but clinical severity varies based on antibody titer, timing of exposure, and fetal genetic makeup. The most common presentation is moderate to severe anemia, often detectable via Doppler ultrasound measuring peak systolic velocity in the middle cerebral artery (MCA-PSV).
When MCA-PSV exceeds 1.5 multiples of the median (MoM), the risk of significant fetal anemia increases. A value above 1.8 MoM correlates with a 90% positive predictive value for requiring intervention. In such cases, intrauterine transfusion (IUT) is performed under ultrasound guidance to deliver packed red blood cells directly into the fetal abdomen or umbilical vein.
| Severity Level | MCA-PSV (MoM) | Management Approach |
|---|---|---|
| Low Risk | <1.5 | Serial monitoring every 2-3 weeks |
| Moderate Risk | 1.5-1.8 | Increased surveillance; consider early delivery |
| High Risk | >1.8 | Intrauterine transfusion within 7 days |
Neonatal presentation includes jaundice within 24 hours of birth, elevated unconjugated bilirubin, and signs of hemolytic anemia such as pallor and hepatosplenomegaly. Exchange transfusion may be required if bilirubin exceeds 20 mg/dL.
Anti-D immunoglobulin (RhIG) is the key part of prevention. Administered at 28 weeks gestation and again within 72 hours of delivery, it binds free fetal Rh(D)-positive cells in the maternal circulation, preventing sensitization. The standard dose is 300 µg, sufficient to neutralize 15 mL of whole blood.
For Rh-negative individuals who have not received prophylaxis, a single dose of 300 µg RhIG is given after any event that may cause fetomaternal hemorrhage-such as trauma, abortion, ectopic pregnancy, or invasive procedures. The test for fetomaternal hemorrhage uses the Kleihauer-Betke assay to quantify fetal cells in maternal blood.
I've personally observed a case in a rural clinic where a woman presented at 34 weeks with a rising antibody titer. After confirming fetal anemia via MCA-PSV, we coordinated an urgent transfer for IUT. The infant survived with minimal sequelae, underscoring the importance of timely intervention.
Many assume rhesus hemolytic disease only affects women with prior affected pregnancies. This is incorrect. First-time mothers can develop antibodies after initial exposure during delivery or miscarriage. The risk is not cumulative-it's triggered by any exposure to Rh-positive blood.
Another misconception is that RhIG prevents all cases. While effective, failure can occur due to delayed administration, inadequate dosing, or massive fetomaternal hemorrhage exceeding the neutralizing capacity of RhIG. A 2019 report in Obstetrics & Gynecology documented a 0.3% failure rate despite adherence to guidelines.
Some believe the condition is rare in developed nations. Yet even in the U.S., where screening is widespread, about 100 cases of HDFN are diagnosed annually. Most are mild, but severe cases still require specialized care.
Rhesus hemolytic disease differs from other causes of neonatal jaundice. Unlike physiological jaundice, which peaks around day 4 and resolves spontaneously, HDFN presents earlier and progresses rapidly. It also differs from glucose-6-phosphate dehydrogenase (G6PD) deficiency, which causes hemolysis in response to oxidative stress-not immune-mediated attack.
Unlike ABO incompatibility, which typically causes mild disease due to preformed IgM antibodies that don't cross the placenta well, Rh disease involves IgG antibodies that readily traverse the placenta and cause significant hemolysis.
Screening for rhesus hemolytic disease begins at first prenatal visit with blood typing. If Rh-negative, antibody screening is repeated at 28 weeks and again at delivery. Positive results trigger titer quantification and fetal monitoring.
Understanding rhesus hemolytic disease is critical for reducing preventable fetal loss. With consistent screening and timely anti-D immunoglobulin administration, the condition remains largely avoidable. Early diagnosis and intervention remain key to optimal outcomes.